Cognito Therapeutics, a Massachusetts-based neurotechnology company developing non-invasive therapies for neurodegenerative disorders, has closed an oversubscribed $105 million Series C financing round. The round was led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, with participation from Apollo Health Ventures, Benvolio Group, New Vintage and other investors.
The company will use the proceeds to advance its investigational Spectris platform, which delivers coordinated visual and auditory stimulation designed to modulate neural activity in patients with Alzheimer’s disease. Spectris is prescribed by physicians and used at home, aiming to "evoke coordinated neural activity, across interconnected networks, through non-invasive visual and auditory stimulation," according to the company.
Cognito’s HOPE pivotal study evaluating Spectris AD Therapy is fully enrolled, with topline data expected later this year. The new funding will support the pivotal data readout, preparation for FDA submission, continued clinical development, and anticipated commercialization in 2027. The company also plans to expand the Spectris platform into additional neurodegenerative indications through collaborations, including with the WVU Rockefeller Neuroscience Institute.
"Cognito represents a rare convergence of rigorous neuroscience research, clinical validation, elegant engineering, and a deep understanding of patient needs," said Gerald Chan, founder of Morningside Ventures and chairman of the board at Cognito. "Spectris has the potential to redefine how a broad category of neurodegenerative diseases are treated, by moving therapy into the home, reducing burden on patients and caregivers, and scaling impact globally. We are proud to continue supporting Cognito as it advances toward regulatory submission and broader clinical impact."
Cognito has steadily expanded its clinical and strategic footprint. In 2023, it raised $73 million in Series B funding, following a $50 million round in 2022 that coincided with data indicating reduced white matter atrophy in Alzheimer’s patients treated with its proprietary gamma-sensory stimulation. The company also received FDA Breakthrough Device Designation in 2021 for its non-invasive neurostimulation device.
With the latest financing, Cognito is positioning Spectris as a home-based neurotechnology platform targeting Alzheimer’s disease and potentially other neurodegenerative conditions.
Click here for the original news story.